11/21
04:11 pm
bmrn
CAMP4 Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
CAMP4 Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/20
11:12 am
bmrn
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock [Yahoo! Finance]
Low
Report
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock [Yahoo! Finance]
11/19
07:02 pm
bmrn
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
11/16
10:47 am
bmrn
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 [Yahoo! Finance]
Low
Report
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 [Yahoo! Finance]
11/16
10:45 am
bmrn
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Low
Report
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
11/15
08:04 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
Medium
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
11/7
09:50 am
bmrn
Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) [Yahoo! Finance]
Low
Report
Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) [Yahoo! Finance]
11/6
05:40 pm
bmrn
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market Evolution - Technavio [Yahoo! Finance]
Low
Report
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market Evolution - Technavio [Yahoo! Finance]
11/6
08:00 am
bmrn
BioMarin to Participate in Three Upcoming Investor Conferences
Low
Report
BioMarin to Participate in Three Upcoming Investor Conferences
11/6
06:32 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/5
11:04 am
bmrn
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term [Yahoo! Finance]
11/4
02:41 pm
bmrn
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" [Yahoo! Finance]
Low
Report
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" [Yahoo! Finance]
10/30
03:35 pm
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $93.00 to $81.00. They now have a "neutral" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $93.00 to $81.00. They now have a "neutral" rating on the stock.
10/30
02:19 pm
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Cantor Fitzgerald from $110.00 to $90.00. They now have an "overweight" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Cantor Fitzgerald from $110.00 to $90.00. They now have an "overweight" rating on the stock.
10/30
02:16 pm
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $93.00 to $84.00. They now have a "hold" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $93.00 to $84.00. They now have a "hold" rating on the stock.
10/30
01:03 pm
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at JPMorgan Chase & Co. from $110.00 to $109.00. They now have an "overweight" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at JPMorgan Chase & Co. from $110.00 to $109.00. They now have an "overweight" rating on the stock.
10/30
11:28 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Evercore ISI from $115.00 to $105.00. They now have an "outperform" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Evercore ISI from $115.00 to $105.00. They now have an "outperform" rating on the stock.
10/30
11:28 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $80.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $80.00 price target on the stock.
10/30
10:08 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $104.00 to $106.00. They now have a "buy" rating on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $104.00 to $106.00. They now have a "buy" rating on the stock.
10/30
08:00 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Robert W. Baird from $72.00 to $65.00. They now have a "neutral" rating on the stock.
Medium
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Robert W. Baird from $72.00 to $65.00. They now have a "neutral" rating on the stock.
10/30
07:27 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
10/29
04:03 pm
bmrn
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Medium
Report
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
10/28
05:36 pm
bmrn
BioMarin Pharmaceutical Q3 2024 Earnings Preview Oct. 28, 2024 5:35 PM ET By: Nilanjana Basu , SA News Editor [Seeking Alpha]
Low
Report
BioMarin Pharmaceutical Q3 2024 Earnings Preview Oct. 28, 2024 5:35 PM ET By: Nilanjana Basu , SA News Editor [Seeking Alpha]
10/24
06:41 am
bmrn
BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth [Yahoo! Finance]
10/17
11:31 am
bmrn
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock [Yahoo! Finance]
Low
Report
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock [Yahoo! Finance]